Reshma Kewalramani
Also at Vertex Pharmaceuticals Inc
About
Dr. Reshma Kewalramani holds a strong academic foundation with a B.A. and M.D. from Boston University School of Medicine, complemented by the completion of the General Management Program at Harvard Business School. She also completed her internship, residency, and fellowship at prestigious institutions including Massachusetts General Hospital and Brigham and Women’s Hospital.
Starting her tenure at Vertex in February 2017 as Senior Vice President, Late Development, she quickly ascended the leadership ladder by assuming the roles of Executive Vice President and Chief Medical Officer in April 2018 and ultimately becoming the President, CEO, and Director in April 2020. During her time at Vertex, she has played an instrumental role in driving innovation and expanding the company’s pipeline.
Prior to her contributions at Vertex, she built a robust career at Amgen Inc., where she held increasing roles of responsibility, culminating in senior leadership positions. Additionally, her experience as an industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee further underscores her influence and commitment in the biotechnology sector.
$VRTX Performance Under Reshma Kewalramani
Past Roles
Fixed Compensation
Performance Compensation
Annual Cash Bonus
The Annual Cash Bonus for 2023 is calculated based on several performance metrics and targets. Below is a detailed breakdown:
Calculation: $1,800,000 × 150% × 150% = $4,050,000.
Stock Awards
Reshma Kewalramani’s stock awards for 2023 comprise both Performance Stock Units (PSUs) and Time-Based Restricted Stock Units (RSUs). The details are as follows:
Performance Stock Units (PSUs)
Time-Based Restricted Stock Units (RSUs)
Additionally, Reshma Kewalramani received a performance rating of "Leading Exemplary" which coupled with the maximum individual performance factor (150%) contributed to the bonus calculation.
These performance compensation components encompass both cash and share-based awards that are contingent upon the achievement of prescribed corporate and individual performance metrics.